Spleen deficiency with dampness pattern diarrhea is a diagnosis rooted in traditional Chinese medicine that overlaps substantially with chronic functional diarrhea and diarrhea-predominant irritable bowel syndrome as understood in Western medicine. In traditional medical theory, the condition arises when the digestive system loses its capacity to transform and transport fluids, producing loose stools, fatigue, poor appetite, and abdominal discomfort. Clinically, Weiling Decoction has been used for such patients for years, but the pharmacological basis of its effects has remained poorly characterized. The new study set out to close that gap by combining modern analytical chemistry with high-throughput genomic sequencing.

The research team, led by corresponding author Ying Cai, first established a mouse model of the syndrome by exposing Kunming mice to high-humidity environments and administering oral lard, a combination designed to replicate the cold, damp conditions and dietary factors associated with the disorder. The team then turned to an ultra-high-performance liquid chromatography tandem mass spectrometry workflow, known as UHPLC-MS/MS, to chemically fingerprint Weiling Decoction. This analysis identified twenty primary bioactive compounds in the formula, including vicenin-1, inosine, and chlorogenic acid, each of which has documented anti-inflammatory or metabolic activity in previous literature.

With the chemical profile in hand, the researchers evaluated how the formula performed therapeutically. Histological examinations of small intestinal tissue revealed that treated mice showed a marked restoration of villus length, the finger-like projections that absorb nutrients in the gut and are often damaged or shortened in diarrheal disease. Treated animals also exhibited a higher density of goblet cells per unit area, specialized cells that produce the protective mucus layer lining the intestinal wall. These structural changes suggest that the decoction does more than suppress symptoms; it appears to actively support the repair and maintenance of the intestinal mucosal barrier.

Biochemical assays reinforced the picture of a remedy that rebalances disrupted signaling networks. Serum levels of cyclic adenosine monophosphate, or cAMP, a molecule central to regulating fluid secretion in the gut, rose in treated mice alongside increases in D-xylose, a marker of intestinal absorptive capacity, and gastrin, a hormone that stimulates digestive function. Meanwhile, levels of cyclic guanosine monophosphate, or cGMP, and vasoactive intestinal peptide, or VIP, both of which promote intestinal secretion and can exacerbate diarrhea when overproduced, were reduced. Together these shifts indicate that the formula helps recalibrate what the researchers describe as the gastrointestinal-water-energy regulatory network, a coordinated system of hormonal and second-messenger signals that governs how the gut manages fluids and energy.

The heart of the study lies in its microbiome analysis. Using 16S rRNA gene sequencing, the researchers surveyed the bacterial populations in the small intestinal contents of the mice and found that treatment with Weiling Decoction significantly increased the relative abundance of three bacterial genera: Limosilactobacillus, Dwaynesavagella, and Paramuribaculum. Limosilactobacillus, a genus that includes well-known probiotic species, has been repeatedly linked to gut barrier protection and anti-inflammatory effects. Shifts in these bacterial populations suggest the decoction works in part by nurturing a microbial community better equipped to maintain intestinal homeostasis.

To probe what these microbial changes might mean functionally, the team applied PICRUSt2, a computational tool that predicts the metabolic capabilities of microbial communities based on their genetic profiles. The analysis pointed to secondary bile acid biosynthesis as a potentially critical mechanistic pathway. Secondary bile acids are produced when gut bacteria chemically modify the bile acids released by the liver, and a growing body of research links these microbial metabolites to intestinal immune regulation, epithelial barrier integrity, and metabolic signaling. The finding is consistent with recent work showing that gut symbionts can alleviate metabolic and inflammatory disease through secondary bile acid pathways, and it places Weiling Decoction’s effects within a rapidly expanding framework of microbiome-mediated pharmacology.

The study’s authors are careful to frame their findings as correlative rather than definitively causal, noting that the results suggest a microbiota-associated pharmacological mechanism rather than proving one outright. Direct evidence that transplanting the altered microbiota reproduces the therapeutic effect, for instance through fecal microbiota transplantation experiments, remains a logical next step. Nonetheless, the convergence of histological repair, biochemical normalization, and microbial restructuring in the same animals provides a coherent and testable model for how the formula may exert its clinical effects.

From a broader perspective, the research speaks to a growing scientific interest in what traditional Chinese medicine practitioners call syndrome-matched treatment, the idea that therapies should be tailored not just to a disease label but to the specific pattern of dysfunction an individual patient exhibits. By characterizing both the chemical constituents of Weiling Decoction and the molecular and microbial consequences of its administration, the study provides what the authors describe as a biotechnological basis for such syndrome-targeted approaches to gastrointestinal disorders. The data underlying the microbiome analysis have been deposited in the NCBI Sequence Read Archive under accession number PRJNA1346698, allowing other researchers to scrutinize and extend the findings.

Chronic diarrhea remains a substantial global health burden, and conventional treatments often manage symptoms without addressing the underlying disruptions in gut ecology and signaling that drive recurrence. If the mechanisms identified in this mouse model hold up in further studies, including controlled human trials, Weiling Decoction could offer a template for developing microbiome-directed therapies that restore gastrointestinal function by working with, rather than against, the body’s resident microbial communities. For now, the study stands as a compelling example of how modern analytical tools, from mass spectrometry to gene sequencing, can illuminate the biological logic hidden within traditional remedies and potentially translate ancient clinical wisdom into the pharmacological language of the twenty-first century.

Subject of Research: Weiling Decoction alleviates spleen deficiency with dampness pattern diarrhea through modulation of intestinal microbiota

Article Title: Integrated UHPLC–MS/MS and 16S rRNA sequencing reveals that Weiling Decoction alleviates spleen deficiency with dampness pattern diarrhea by modulating intestinal microbiota

Article References: Yu, D., Long, Q., Tian, Q., Zhang, X., Li, D., Tan, Z., & Cai, Y. (2026). Integrated UHPLC–MS/MS and 16S rRNA sequencing reveals that Weiling Decoction alleviates spleen deficiency with dampness pattern diarrhea by modulating intestinal microbiota. 3 Biotech, 16(10), Article 421. https://doi.org/10.1007/s13205-026-05052-y

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05052-y

Keywords: Weiling Decoction, traditional Chinese medicine, intestinal microbiota, diarrhea, 16S rRNA sequencing, UHPLC-MS/MS, spleen deficiency with dampness pattern, secondary bile acids, gut barrier, PICRUSt2, Limosilactobacillus, gastrointestinal health

LCA is a secondary bile acid produced when intestinal microorganisms transform primary bile acids. It participates in bile acid metabolism and can influence cellular signaling, energy balance, and inflammation. At high concentrations, however, LCA has been linked to cholestasis, impaired bile flow, obstruction of bile ducts, hepatocyte injury, and cell death. This apparent contradiction has complicated efforts to explore LCA as a possible therapy. Earlier work had shown that LCA levels rise during caloric restriction, a dietary intervention associated with longer lifespan and improved metabolic health in several organisms.

Caloric restriction is thought to activate a network of metabolic responses that improve glucose handling, mitochondrial function, stress resistance, and tissue maintenance. LCA has been proposed as one of the circulating molecules that may help transmit some of these benefits. In animal studies, the bile acid has been associated with increased muscle NAD+ levels, improved grip strength and endurance in aged mice, and longer lifespan in nematodes and fruit flies. Yet the doses required to produce such effects must be distinguished from the much higher exposures known to damage the liver.

To investigate this dose boundary, a team led by Sheng-Cai Lin of Henan University and Xiamen University first studied obese mice. The animals received LCA in their drinking water at a concentration of 1 gram per liter, producing blood levels of approximately 1 micromole per liter. That exposure was designed to resemble the concentration observed during caloric restriction rather than the substantially higher levels used in toxicology experiments. After four weeks, the mice had lower hepatic triglyceride content, reduced fatty liver, and improved glucose metabolism.

The researchers also examined the molecular pathway behind the response. Liver-specific knockout mice lacking AMPKα did not receive the same metabolic benefits, implicating AMP-activated protein kinase as a central mediator. AMPK is an energy-sensing enzyme that becomes active when cellular energy supplies are limited. Once activated, it can suppress energy-intensive processes such as lipid synthesis while promoting fatty-acid oxidation and other pathways that help restore energy balance. The results indicate that low-dose LCA may improve liver metabolism through this energy-sensing system.

The safety picture changed sharply when the dose was increased. At 250 milligrams per kilogram per day, hepatic LCA concentrations reached about 14 micromoles per liter, and the mice developed clear signs of liver injury. This contrast provided direct evidence for a dose-dependent safety window: concentrations near those associated with caloric restriction appeared beneficial, while substantially higher exposure became toxic. The distinction is particularly important because bile acids can accumulate in the liver and exert effects that are not predicted simply by the administered dose.

The team next tested LCA in cynomolgus macaques with fatty liver. Translating doses from rodents to primates proved more complicated than expected. The monkeys rejected the formulation used in the mouse experiments, so the researchers developed a phospholipid-coated preparation suspended in fish oil. When they administered a mouse-equivalent dose calculated by body-surface-area conversion—9.6 milligrams per kilogram—the animals’ serum LCA concentrations rose above 6 micromoles per liter. Within one week, alanine aminotransferase and aspartate aminotransferase, enzymes commonly used to detect liver injury, increased significantly.

That result demonstrated why standard interspecies dose conversion can be unreliable for compounds whose absorption, metabolism, and circulation differ between animals. The researchers therefore conducted a dose-titration study in the macaques and identified two lower regimens: 0.25 milligrams per kilogram and 0.5 milligrams per kilogram, administered twice daily. These schedules maintained steady-state blood concentrations of approximately 0.8 to 1 micromole per liter, close to the target range observed in the mouse experiments, without producing biochemical evidence of liver damage.

After 13 weeks, macaques receiving either low-dose regimen showed significant histological improvement in hepatic steatosis, the abnormal accumulation of fat inside liver cells. Their body weight, blood lipids, and glucose levels remained stable, while ALT, AST, creatinine, and blood counts showed no treatment-related abnormalities. The findings do not establish that LCA is ready for human use, and the study involved early-stage fatty liver rather than advanced disease with severe hyperglycemia or hypertriglyceridemia. Longer studies will be needed to assess tissue distribution, sex-related differences, chronic toxicity, and responses in more advanced models. Nevertheless, the work provides the first reported evidence in a non-human primate that a carefully controlled, caloric-restriction-like concentration of LCA may alleviate fatty liver through hepatic AMPK activation without detectable toxicity.

Article Title: Lithocholic acid alleviates fatty liver in mice and non-human primate macaques

News Publication Date: 23-Jul-2026

Web References: https://doi.org/10.1093/lifemeta/loag023

References: Life Metabolism, DOI: 10.1093/lifemeta/loag023

Image Credits: Higher Education Press

Keywords: lithocholic acid, LCA, fatty liver, metabolic dysfunction-associated steatotic liver disease, caloric restriction, AMPK, bile acids, cynomolgus macaques, liver metabolism, hepatotoxicity